spacer
home > pmps > winter 2002 > modified-release oral solid dosage forms - part i: coating and matrix formation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Modified-Release Oral Solid Dosage Forms - Part I: Coating and Matrix Formation

This article provides a comprehensive review of the basics of matrix and coating systems on which new drug delivery companies have based their products. It focuses on the investigation of the underlying technical principles of oral solid dosage forms (tablets and particles) by classifying them as matrix or coating systems. The materials chemistry and processing (formulation and formation methods) of matrix or coating oral solid dosage forms have been investigated. Processing of commercial matrix or coating systems is different.

The conventional processing described provides the basics for what is now all-in-one granulation using fluid beds (top-spray for matrices and bottom or tangential-spray for coatings). Each system's specific parameters (polymer hydration and gel formation for matrices, insolubility for coatings) and common parameters (particle size, shape of all particles, drug per cent, polymer blend solubility, flexibility and compressibility) are discussed. The current trends resulted from these basic technical formation principles.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Emmanuel Dimotakis PhD and Robert A Nash PhD, Department of Chemical
and Pharmaceutical Engineering at the New Jersey Institute of Technology

Dr Emmanuel Dimotakis joined Sun Chemical as an Associate Scientist in 1998 and is currently a Scientist II. His expertise is in product development with emphasis on nanostructure-property relationships and formulation/rheology of polymers for coatings/colorants, nanomaterials and lithography. He has introduced products into the market, published 15 articles, 3 US/WO Patents (others are pending) and 12 government reports to NASA/DOD.

He was formerly with E. Merck and before that with MER Corporation. Dr Dimotakis received his PhD in Chemistry at Michigan State University in 1990 and undertook Postdoctoral work in Materials Science and Engineering at the University of Illinois at Urbana-Champaign.

Dr Robert A Nash is Adjunct Professor of Pharmaceutical Engineering at Stevens Institute of Technology in Hoboken, USA. Before that he taught at NJIT and St John's University.

Dr Nash spent 24 years in the US pharmaceutical industry with Merck, Lederle and the Purdue Frederick Co. in roles varying from Researcher to Manager of Pharmaceutical R&D. Dr Nash is Co-Editor of Pharmaceutical Process Validation published by Marcel Dekker & Co, New York. He is also a Consultant to the US FDA on validation and GMP matters.


spacer
Dr Emmanuel Dimotakis
spacer
spacer
spacer
Dr Robert A Nash
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement